The VMRC’s most notable achievement in AMR innovation during FY25 was the development of Renal Guard Technology (RGT), a proprietary platform engineered to reduce the nephrotoxicity associated with potent antibiotics such as polymyxin B, colistin, and amikacin.

VMRC also began early-stage studies using gene-editing tools to design new antimicrobial agents that can target and overcome resistance mechanisms in pathogens. Furthermore, the global recognition of VMRC’s AMR work was reinforced when three drug candidates were featured in the WHO’s latest Global Antibacterial Pipeline Report. Of the nine AMR candidates listed from India, three originated from VMRC, demonstrating its significant contribution to national and global efforts against AMR.

In addition to its work in infectious disease, VMRC has remained committed to advancing treatments in nephrology. The organisation has made important progress in developing and optimising its Renal Guard Technology (RGT), which mitigates the adverse renal effects of antibiotics frequently used in critical care and infectious disease scenarios.

This initiative aligns with VMRC’s broader strategy to enhance the therapeutic index of essential drugs by incorporating kidney-protective mechanisms. In terms of pipeline advancement:

• VRP-034 completed preclinical development
• Enhance understanding of drug mechanisms

These programs reflect VMRC’s sustained focus on enhancing renal outcomes and offering safer therapeutic alternatives to conventional treatments.